首页> 中文期刊> 《当代医学》 >活血软肝丸治疗代偿期乙肝肝硬化的疗效评价

活血软肝丸治疗代偿期乙肝肝硬化的疗效评价

         

摘要

Objective To analyze the effect above the application of invigorate the circulation of soft liver pill treatment of hepatitis b cirrhosis compensatory period.Methods The selected object of study for 90 cases of patients with early liver cirrhosis. according to their hospital registration time, they will be divided into the control group and the research group, and there are 45 cases in each group, the patients in the two groups were given conventional treatment, based on this, the research group combined with Huoxue Soft Liver pill treatment while the control group using Silibin Meglumine Tablets treatment, in the oral way, after 6 months of treatment, to observe clinical effect and the changes of the indicators happen to the liver function and liverfibrosis of two groups patients before and after the treatment , and give the comparative analysis.Results Before treatment, there is no statistically significant difference between the two groups of patients with liver function and liverfibrosis index contrast, after treatment, two groups of patients with liver function and liverfibrosis indexes are improved, and the improvement of the study group was superior to that of the control group, two groups of index contrast difference is statistically significant (P<0.05).Conclusion Based on the conventional antiviral treatment with oral soft invigorate the liver pill treatment of compensatory phase of hepatitis b cirrhosis of the liver, it is beneficial for the improvement of the liver blood circulation and hepatic cell metabolism, it can reduce the inflammatory reaction and accelerate liverfibrosis reversal to obtain a significant result, it is worth popularization in clinical application.%目的:探讨分析应用活血软肝丸治疗代偿期乙肝肝硬化的效果。方法研究对象为90例早期乙肝肝硬化患者,根据其住院时间顺序将其随机均分为对照组与研究组(n=45),2组患者均予以常规抗病毒治疗,在此基础上,研究组服用活血软肝丸治疗,口服,对照组口服水飞蓟宾胶囊(水林佳)治疗,治疗6个月后,观察2组患者临床效果和治疗前后肝功能、肝纤维化指标等所发生的变化,并予以比较分析。结果研究组患者的疗效总有效率为91.1%(41例),明显高于对照组患者的75.6%(34例),差异存在统计学意义(P<0.05)。治疗前,2组患者肝功能和肝纤维化指标对比差异不具有统计学意义;治疗后,2组患者肝功能和肝纤维化指标均有所改善,其中研究组改善情况显著优于对照组,2组差异具有统计学意义(P<0.05)。结论基于常规抗病毒治疗加口服活血软肝丸治疗代偿期乙肝肝硬化,有利于机体肝脏血液循环和肝细胞代谢的改善,可减轻炎症反应,加速肝纤维化逆转,获得显著的效果,在临床中值得推广应用。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号